FDA truncates drug approval process; Makary pushes for more OTC drugs; Inside the rocky ride for Recursion Pharmaceuticals.
Tamar Abrams had a lousy couple of years in 2022 and '23. Both her parents died; a relationship ended; she retired from ...
FDA Commissioner Dr. Marty Makary explains the agency’s decision to lift the warning on hormone replacement therapy and addresses safety and supply concerns.
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and ...
A system that allows drug makers to profit from restricted access will never liberalize on its own—and patients will continue ...
In a NEJM article, Commissioner Martin Makary and top deputy Vinay Prasad argued that the new policy should lower development costs and speed development without compromising agency standards.
Politico has reported that the White House isn’t happy with the FDA’s recent actions surrounding vaccines, fueling public scrutiny of internal decision-making at the regulator. | Politico has reported ...
Drug sponsors should nevertheless bolster their application with “confirmative evidence,” chief regulators Marty Makary and Vinay Prasad said on Wednesday, including mechanistic data or findings from ...
Even as Novo and U.S. rival Eli Lilly had moved to aggressively cut prices on their GLP-1 weight-loss drugs, Hims announced plans to offer a compounded oral semaglutide pill for $49 - a version of ...
Drugmakers are urging the FDA to reassess the regulatory process of switching medications from prescription to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results